Michael I. Keller, MD

Michael I. Keller, MD
San Diego Arthritis and Osteoporosis Research, San Diego, CA

Address: Michael I. Keller, MD, 5555 Reservoir Drive, Suite 202, San Diego, CA 92120; e-mail [email protected]

The author has indicated that he has received grant or research support from the Wyeth, Pfizer, Proctor and Gamble, Sanofi, NPS, and Alexis corporations and is on the speakers’ bureaus of the Abbott, Merck, and Proctor and Gamble corporations.

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Michael I. Keller, MD
San Diego Arthritis and Osteoporosis Research, San Diego, CA

Address: Michael I. Keller, MD, 5555 Reservoir Drive, Suite 202, San Diego, CA 92120; e-mail [email protected]

The author has indicated that he has received grant or research support from the Wyeth, Pfizer, Proctor and Gamble, Sanofi, NPS, and Alexis corporations and is on the speakers’ bureaus of the Abbott, Merck, and Proctor and Gamble corporations.

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Michael I. Keller, MD
San Diego Arthritis and Osteoporosis Research, San Diego, CA

Address: Michael I. Keller, MD, 5555 Reservoir Drive, Suite 202, San Diego, CA 92120; e-mail [email protected]

The author has indicated that he has received grant or research support from the Wyeth, Pfizer, Proctor and Gamble, Sanofi, NPS, and Alexis corporations and is on the speakers’ bureaus of the Abbott, Merck, and Proctor and Gamble corporations.

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.